|
Synonyms: GSK3882347
Compound class:
Synthetic organic
Comment: Luxafimloc (also known as GSK3882347) is an orally bioavailable, mannose-containing small molecule with promising anti-virulence activity against uropathogenic Gram-negative bacteria. The chemical structure is claimed in GSK patent WO2020012336A1 [1] and was presented during the ACS Fall 2026 meeting's First Time Disclosures session [2].
|
|
|||||||||||||||||||||||||||||||||||
| References |
|
1. Bishop MJ, Colandrea VJ, Li Y, Stewart EL, Strambeanu I, Widdowson KL, Janetka JW, McGrane LK. (2020)
C-mannoside compounds useful for the treatment of urinary tract infections. Patent number: WO2020012336A1. Assignee: GlaxoSmithKline Intellectual Property Development Ltd, Fimbrion Therapeutics Inc. Priority date: 08/07/2019. Publication date: 16/01/2020. |
|
2. McGrane L, Martin S, Hibbing M, Stewart E, Eddershaw P, Meinhold D, Shewchuk L, Wang L, Strambeanu I, Colandrea V et al..
4536652 - Discovery of GSK3882347, an orally bioavailable, FimH antagonist for uncomplicated urinary tract infections. Accessed on 16/09/2026. Modified on 16/09/2026. MEDI First Time Disclosures: - ACS Fall 2026 - American Chemical Society, https://acs.digitellinc.com/live/37/session/594481 |